Large Inflow of Money Witnessed in Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited (TEVA) : Teva Pharmaceutical Industries Limited (TEVA) had a healthy money flow of $1.13 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $4.88 million, whereas, investors only sold shares worth $3.75 million on downticks. The stock closed the day with an up-down ratio of 1.3.The money flow in the block trades to the tune of $0.98 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.98 million worth of transactions were on upticks. Teva Pharmaceutical Industries Limited (TEVA) stock slid $0.03 intraday and traded at 50.28, a change of -0.06% over previous days close. However, for the week, the company shares are 0.46% compared to previous weeks close.


Teva Pharmaceutical Industries Limited (TEVA) : The highest short term price target forecast on Teva Pharmaceutical Industries Limited (TEVA) is $100 and the lowest target price is $58. A total of 18 equity analysts are currently covering the company. The average price of all the analysts is $74.3 with a standard deviation of $9.29. The stock has recorded a 20-day Moving Average of 1.71% and the 50-Day Moving Average is 2.94%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.35 and $50.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.52, notching a gain of 0.42% for the day. The total traded volume was 5,794,347 . The stock had closed at $50.31 on the previous day.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *